- Home
- STRO vs VYGR Comparison
STRO vs VYGR Comparison
Compare STRO & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- VYGR
- Stock Information
- Founded
- STRO 2003
- VYGR 2013
- Country
- STRO United States
- VYGR United States
- Employees
- STRO N/A
- VYGR N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- VYGR Health Care
- Exchange
- STRO Nasdaq
- VYGR Nasdaq
- Market Cap
- STRO 172.8M
- VYGR 342.5M
- IPO Year
- STRO 2018
- VYGR 2015
- Fundamental
- Price
- STRO $1.93
- VYGR $5.78
- Analyst Decision
- STRO Strong Buy
- VYGR Strong Buy
- Analyst Count
- STRO 7
- VYGR 9
- Target Price
- STRO $12.14
- VYGR $16.44
- AVG Volume (30 Days)
- STRO 1.4M
- VYGR 472.1K
- Earning Date
- STRO 11-13-2024
- VYGR 11-12-2024
- Dividend Yield
- STRO N/A
- VYGR N/A
- EPS Growth
- STRO N/A
- VYGR N/A
- EPS
- STRO N/A
- VYGR 0.47
- Revenue
- STRO $160,955,000.00
- VYGR $163,784,000.00
- Revenue This Year
- STRO N/A
- VYGR N/A
- Revenue Next Year
- STRO N/A
- VYGR N/A
- P/E Ratio
- STRO N/A
- VYGR $12.39
- Revenue Growth
- STRO 230.90
- VYGR 3.40
- 52 Week Low
- STRO $1.70
- VYGR $5.19
- 52 Week High
- STRO $6.13
- VYGR $11.72
- Technical
- Relative Strength Index (RSI)
- STRO 29.88
- VYGR 42.16
- Support Level
- STRO $1.70
- VYGR $5.53
- Resistance Level
- STRO $3.01
- VYGR $6.55
- Average True Range (ATR)
- STRO 0.21
- VYGR 0.32
- MACD
- STRO -0.02
- VYGR -0.05
- Stochastic Oscillator
- STRO 17.56
- VYGR 21.55
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.